doi: 10.1006/bbrc.2000.2800 17
The current clinical evidence of intravenous glutathione for skin lightening is limited to a single study with a dubious study design and apparently flawed analysis of results, casting doubt on the drug's efficacy and reported adverse effects, with no evidence to prove its efficacy.There was only one placebo-controlled study on intravenous glutathione showing 37.5% response versus 18.7% placebo, and IV glutathione is contraindicated due to lack of efficacy and side effects
In this context, research strategies aimed at the selective inhibition of FOXO proteins including the use of peptide analogs such as FOXO4-DRI represent a promising approach for investigating the modulation of metabolic pathways, with potential relevance to diabetes-related complications
Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB and Nelson WG